Unknown

Dataset Information

0

Overexpression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx-/Wzy-dependent pathway enhances production of defined modal length O-polysaccharide polymers for use as haptens in glycoconjugate vaccines.


ABSTRACT:

Aims

O-polysaccharide (OPS) molecules are protective antigens for several bacterial pathogens, and have broad utility as components of glycoconjugate vaccines. Variability in the OPS chain length is one obstacle towards further development of these vaccines. Introduction of sizing steps during purification of OPS molecules of suboptimal or of mixed lengths introduces additional costs and complexity while decreasing the final yield. The overall goal of this study was to demonstrate the utility of engineering Gram-negative bacteria to produce homogenous O-polysaccharide populations that can be used as the basis of carbohydrate vaccines by overexpressing O-polysaccharide chain length regulators of the Wzx-/Wzy-dependent pathway.

Method and results

The O-polysaccharide chain length regulators wzzB and fepE from Salmonella Typhimurium I77 and wzz2 from Pseudomonas aeruginosa PAO1 were cloned and expressed in the homologous organism or in other Gram-negative bacteria. Overexpression of these Wzz proteins in the homologous organism significantly increased the proportion of long or very long chain O-polysaccharides. The same observation was made when wzzB was overexpressed in Salmonella Paratyphi A and Shigella flexneri, and wzz2 was overexpressed in two other strains of P. aeruginosa.

Conclusions

Overexpression of Wzz proteins in Gram-negative bacteria using the Wzx/Wzy-dependant pathway for lipopolysaccharide synthesis provides a genetic method to increase the production of an O-polysaccharide population of a defined size.

Significance and impact of the study

The methods presented herein represent a cost-effective and improved strategy for isolating preferred OPS vaccine haptens, and could facilitate the further use of O-polysaccharides in glycoconjugate vaccine development.

SUBMITTER: Hegerle N 

PROVIDER: S-EPMC6726474 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC368303 | biostudies-literature
| S-EPMC3414684 | biostudies-literature
| S-EPMC2921718 | biostudies-literature
| S-EPMC6320544 | biostudies-literature
| S-EPMC5897956 | biostudies-literature
| S-EPMC165269 | biostudies-literature
| S-EPMC2932511 | biostudies-other
| S-EPMC4936365 | biostudies-literature
| S-EPMC2168344 | biostudies-literature
| S-EPMC6961727 | biostudies-literature